The Phase III API-CAT trial found that extended anticoagulant therapy with reduced-dose Eliquis (apixaban) was noninferior to ...
The combination met its primary endpoint of percent weight loss following an 8-week treatment period.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback